Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 6/20 | 0.35 |
| ▸ | NPY1R | P25929 | 4/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25448049 | 1.00 | DPP7 (0.41) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL14887421 | 1.00 | DPP7 (0.41) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL22848364 | 0.93 | DPP4 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL20795868 | 0.93 | DPP4 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL22797764 | 0.93 | DPP4 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL28234596 | 0.93 | DPP4 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL20428137 | 0.89 | NPY4R (0.44) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL29359380 | 0.88 | C3AR1 (0.46) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL16862522 | 0.88 | C3AR1 (0.46) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL28819908 | 0.88 | C3AR1 (0.46) | DPP7DPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054992-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3054991-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9822112-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9676775-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9526801-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160199510-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2016-07-14 | — | — | US | disclosed |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-05-07 | — | — | US | disclosed |
| WO-2015054669-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054659-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | DPP7 3148/4885DPP4 3823/4885DPP8 3371/4885 |
| US-20160199510-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | DPP7 4524/4885DPP4 4708/4885DPP8 4041/4885 |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | DPP7 4524/4885DPP4 4708/4885DPP8 4041/4885 |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | DPP7 3148/4885DPP4 3823/4885DPP8 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.